| Fiasp (fast-acting insulin aspart) / Novo Nordisk |
2019-001281-14: A study that investigates the effects of fast-acting insulin (FIASP®) on blood sugars in comparison to a different fast-acting insulin (NovoRapid®) around exercise in participants with type 1 diabetes Der Einfluss von schnell-wirkendem Insulin (FIASP®) auf den Blutzuckerspiegel im Vergleich zu einem anderen schnell wirkendem Insulin (NovoRapid®) vor, während und nach sportlicher Belastung |
|
|
| Ongoing | 4 | 44 | Europe | Fiasp, Novorapid, Tresiba, A10AB05, Injection, Fast-acting insulin aspart (Fiasp® 100 U/mL) in 3 mL FlexTouch®, Insulin aspart (NovoRapid® 100 U/mL) in 3 mL FlexPen®, Insulin degludec (Tresiba® 100 U/mL) in 3 mL FlexTouch® | Medical University of Graz, Novo Nordisk | Type 1 Diabetes Typ 1 Diabetes Mellitus, Participants in this study have type 1 diabetes which is defined as the lack of own insulin production. Probanden in dieser Studie haben Typ 1 Diabetes Mellitus welches sich durch das Ausbleiben einer körpereigenen Insulinproduktion auszeichnet., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
PLATEAU, NCT04414579: The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus |
|
|
| Recruiting | 4 | 45 | US | Faster Insulin Aspart (Fiasp®), Conventional Insulin Aspart (NovoLog®) | Mountain Diabetes and Endocrine Center | Type 1 Diabetes Mellitus | 03/21 | 03/21 | | |
2019-001631-31: Automated blood glucose control with insulin and glucagon in patients with type 1 diabetes Automatisk regulering af blodsukkeret med insulin og glukagon hos patienter med type 1 diabetes |
|
|
| Not yet recruiting | 4 | 13 | Europe | GlucaGen, FiAsp, SUB02347MIG, SUB08195MIG, Powder and solution for solution for injection, Solution for injection/infusion, GlucaGen, FiAsp(R), insulin aspart | Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen | Patients with type 1 diabetes, Metabolic disease in which a person has high blood glucose values due to insufficient insulin production, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT04620967: Fast-Acting Insulin Aspart and Insulin Pump Settings |
|
|
| Recruiting | 4 | 40 | Europe | Insulin aspart, Fast-acting insulin aspart | Kirsten Nørgaard | Type 1 Diabetes | 06/22 | 06/22 | | |
NCT03659799: Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 40 | Canada | Insulin FiAsp, Insulin Aspart, 60-minutes postprandial exercise, 120-minutes postprandial exercise | Institut de Recherches Cliniques de Montreal | Type 1 Diabetes Mellitus | 12/22 | 03/23 | | |
NCT04772729: Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes? |
|
|
| Not yet recruiting | 4 | 77 | NA | Insulin faster aspart (Fiasp, Novo Nordisk), Insulin aspart (Novo Rapid, Novo Nordisk) | Medical University of Warsaw | Diabetes type1, Diabetes Mellitus, Type 1 | 03/23 | 03/24 | | |
2020-001158-23: Fast-Acting Insulin Aspart and Insulin Pump Settings:“THE FAST PUMP SETTING STUDY” |
|
|
| Not yet recruiting | 4 | 40 | Europe | Fiasp, Novorapid, Solution for injection/infusion, Fiasp, NovoRapid | Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Novo Nordisk A/S | Type 1 diabetes, Participants in this study have type 1 diabetes which is defined as lack of own insulin production Type 1 diabetes er en kronisk sygdom som er karakteriseret ved at man ikke kan producere insulin til at få blodglukose ned., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
MIRE, NCT04381429: Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes |
|
|
| Recruiting | 4 | 40 | Europe | A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP), All patients will have both treatments: NovoRapid + FIASP, F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid) | University Hospital, Strasbourg, France | Cystic Fibrosis-related Diabetes | 08/25 | 08/25 | | |
2017-003399-30: A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetes |
|
|
| Ongoing | 3 | 632 | Europe | ultra-rapid formulation of insulin lispro, Fiasp®, LY900014, Solution for injection, Fiasp® | Eli Lilly and Company, Lilly S.A., Eli Lilly and Company | Diabetes Mellitus, Type 1, Diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2018-004680-31: A comparison of the faster-acting insulin Fiasp® versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation |
|
|
| Not yet recruiting | 3 | 220 | Europe | Solution for injection in pre-filled pen, Solution for injection/infusion, Fiasp, Novorapid | Lene Ringholm, Novo Nordisk | Type 1 and type 2 diabetes during pregnancy and lactation, Insulin requiring diabetes during pregnancy and lactation, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT03770767: Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes |
|
|
| Completed | 3 | 216 | Europe | Faster-acting Aspart insulin Fiasp, Insulin Fiasp, Control (insulin Novorapid), First generation insulin analog | Rigshospitalet, Denmark | Diabetes Mellitus, Pregnancy Complications | 03/23 | 03/23 | | |
NCT04460326: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 137 | US | Insulin glargine, Lantus®, NovoLog, NovoLog®, Insulin Fiasp, Fiasp®, Standard carbohydrate diet | Boston Medical Center, Novo Nordisk A/S | Type 2 Diabetes Treated With Insulin | 05/23 | 05/23 | | |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT04698018: A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes |
|
|
| Completed | 1 | 23 | Europe, RoW | Faster Aspart, Novo Rapid | Novo Nordisk A/S | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 04/23 | 04/23 | | |
FCL, NCT05199714: A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes |
|
|
| Completed | N/A | 12 | Canada | Fiasp, Artificial Pancreas, Pramlintide, Aspart | McGill University Health Centre/Research Institute of the McGill University Health Centre, Juvenile Diabetes Research Foundation | Type 1 Diabetes | 03/23 | 03/23 | | |
CONNECT 1, NCT05069545: A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice |
|
|
| Completed | N/A | 411 | Europe | Insulin degludec, Fast-acting insulin aspart | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | 09/24 | 09/24 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
ACTRN12619001340123: Faster insulin aspart (FiASP) vs. apart using an advanced closed-loop system: Extension study evaluating meal-time glucose control |
|
|
| Not yet recruiting | N/A | 12 | | | Medtronic Diabetes, St Vincent's Hospital Melbourne | type 1 diabetes | | | | |
ACTRN12620000687998: Faster acting insulin aspart (FiASP) vs. insulin aspart using an advanced closed-loop system in type 1 diabetes: 12-month free living study
|
|
|
| Not yet recruiting | N/A | 12 | | | Medtronic Diabetes, St Vincent's Hospital Melbourne | type 1 diabetes | | | | |
| Active, not recruiting | N/A | 24 | | | Medtronic Diabetes, St Vincent's Hospital Melbourne | type 1 diabetes | | | | |
